Cypher Genomics - About the company
Cypher Genomics is an acquired company based in San Diego (United States), founded in 2011 by Ali Torkamani and Ashley Van Zeeland. It operates as a Provider of an interpretation software solution for users of human genome sequencing. Cypher Genomics has raised an undisclosed amount in funding from EvoNexus. The company has 2394 active competitors, including 549 funded and 380 that have exited. Its top competitors include companies like DNAnexus, Sutro Biopharma and Synthego.
Company Details
Provider of an interpretation software solution for users of human genome sequencing. The company offers Mantis, the genome interpretation software as a service offering, and Coral, a biomarker discovery service, to improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions.
- Website
- cyphergenomics.com
- Social
- Registered Address
- San Diego, California
Key Metrics
Founded Year
2011
Location
San Diego, United States
Stage
Acquired
Latest Funding Round
Ranked
476th among 2394 active competitors
Employee Count
83 as on Dec 31, 2022
Exit Details
Acquired by Human Longevity (Nov 30, 2015)
Legal entities associated with Cypher Genomics
Cypher Genomics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Human Longevity, Inc. CIN: 463131906 , United States, Active | Dec 26, 999 | - | 83 (As on Dec 31, 2022) | - |
Cypher Genomics's acquisition details
Cypher Genomics got acquired by Human Longevity on Nov 30, 2015.
Click here to take a look at Cypher Genomics's acquisition in detail
Sign up to download Cypher Genomics' company profile
Cypher Genomics's funding and investors
Cypher Genomics has raised funding over 2 rounds. Its first funding round was on Jul 24, 2014. Its latest funding round was a Seed round on 2015 for $*****. 1 investor participated in its latest round. Cypher Genomics has 2 institutional investors.
Here is the list of recent funding rounds of Cypher Genomics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2015 | 1373 | Seed | 8636 | 8507 | 1814 | 8924 |
Jul 24, 2014 | 2754077 | Seed | 1226740 | 8185072 | 5888367 |
Access funding benchmarks and valuations. Sign up today!View details of Cypher Genomics's funding rounds and investors
Cypher Genomics' founders and board of directors
Founder? Claim ProfileThe founders of Cypher Genomics are Ali Torkamani and Ashley Van Zeeland.
Here are the details of Cypher Genomics' key team members:
- Ali Torkamani: Co-Founder and CSO of Cypher Genomics.
- Ashley Van Zeeland: CoFounder & CEO of Cypher Genomics.
View details of Cypher Genomics's Founder profiles and Board Members
Cypher Genomics' employee count trend
Cypher Genomics has 83 employees as of Dec 22. The total employee count is 36.0% lower than what it was in Dec 21. Here is Cypher Genomics's employee count trend over the years:
Uncover Cypher Genomics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cypher Genomics's Competitors and alternates
Top competitors of Cypher Genomics include DNAnexus, Sutro Biopharma and Synthego. Here is the list of Top 10 competitors of Cypher Genomics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  DNAnexus 2009, Mountain View (United States), Series H | Provider of cloud-based genome informatics & data management platform | $473M | 71/100 | |
2nd | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 71/100 | |
3rd | Synthego 2012, Redwood City (United States), Acquired | Developer of CRISPR-engineered cell and gene therapies | $460M | 69/100 | |
4th |  Avidity Biosciences 2012, San Diego (United States), Public | Develops antibody-siRNA complexes to treat cancer | $143M | 68/100 | |
5th | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $152M | 68/100 | |
6th | Fabric Genomics Oakland (United States), Acquired | AI-based disease diagnosis and genomic analysis tool for providers | $31.3M | 67/100 | |
7th |  Vividion Therapeutics 2016, Oceanside (United States), Acquired | Developing novel drugs based on a proteome-wide ligand and target discovery platform | $271M | 67/100 | |
8th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA-editing technologies for precision medicine | $4M | 67/100 | |
9th | Savara Pharma 2008, Austin (United States), Public | Developer of therapeutics for rare respiratory diseases | $67.8M | 66/100 | |
10th | LifeMine Therapeutics 2016, Cambridge (United States), Series C | Developer of novel drugs from fungi via genome mining and recombinant overexpression | $300M | 66/100 | |
476th | Cypher Genomics 2011, San Diego (United States), Acquired | Provider of an interpretation software solution for users of human genome sequencing | - | 37/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Cypher Genomics's competitors? Click here to see the top ones
Cypher Genomics's Investments and acquisitions
Cypher Genomics has made no investments or acquisitions yet.
Reports related to Cypher Genomics
Here is the latest report on Cypher Genomics's sector:
Are you a Founder ?
FAQs about Cypher Genomics
Explore our recently published companies
- Saga - London based, 2017 founded, Series A company
- Sitel - Gurugram based, 1985 founded, Acquired company
- Zapi - Singapore based, 2025 founded, Unfunded company
- CorpChamber - Jakarta based, 2023 founded, Unfunded company
- Oxynum - Paris based, 2012 founded, Unfunded company
- WAVEE - Tokyo based, 2022 founded, Unfunded company
